Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players
Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Announces Target Price $4
Optimistic Buy Rating for PAVmed Amid Strategic Positioning and Promising Financial Outlook
Express News | American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' Esoguard Esophageal Precancer Test
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
Lucid Diagnostics to Be Deconsolidated From PAVmed's Financial Statements